Regeneron Pharmaceuticals Inc

REGNNASDAQ • USD
ThemeBiotech - Drug Development›Immunology & Autoimmune
781.49 USD
↘ 11.77 (1.48%)AT CLOSE (11:59 AM EDT)
783.40
↗ 1.91 (0.25%)
POST MARKET (AS OF 07:37 PM EDT)
Post Market
AS OF 07:37 PM EDT
783.40
↗ 1.91 (0.25%)
🔴Market: CLOSED

Regeneron Pharmaceuticals Inc (REGN) trades at $781.49 per share. The technical outlook is "Sell" and the fundamental picture shows "Neutral". Key drivers include a robust Altman Z-Score and a bullish Golden Cross on the moving averages. REGN is fairly valued relative to its sector peers based on current multiples.

Technical & fundamental data as of Sep 11, 2026.

Open?$800.00
High?$800.22
Low?$780.81
Prev. Close?$793.26
Volume?444.0K
Avg. Volume?694.7K
VWAP?$784.38
Rel. Volume?0.64x
Bid / Ask
Bid?$780.00 × 560
Ask?$784.25 × 40
Spread?$4.25
Midpoint?$782.13
Valuation & Ratios
Market Cap?80.5B
Shares Out?101.1M
Float?95.7M
Float %?94.6%
P/E Ratio?18.59
P/B Ratio?2.54
EPS?$42.04
Dividend?0.47%
Ex-Dividend?N/A
News
Profile
Regeneron Pharmaceuticals discovers, develops, and commercializes products that fight eye disease, cardiovascular disease, cancer, and inflammation. The company has several marketed products, including low-dose Eylea and Eylea HD, approved for wet age-related macular degeneration and other eye diseases; Dupixent in immunology; Praluent for LDL cholesterol lowering; Libtayo in oncology; Kevzara in rheumatoid arthritis; and Lynozyfic for multiple myeloma. Regeneron has multiple partnerships and collaboration agreements, with Sanofi (Dupixent, others) and Bayer (Eylea) as its largest partners.
Themes
Biotech - Drug Development›Immunology & AutoimmuneHealthcare - Oncology›Immunotherapy & Immuno-OncologyHealthcare - Genomics & Precision Medicine›Gene Therapy & Gene Editing
Employees
15.4K
Market Cap
81.7B
Industry
PHARMACEUTICAL PREPARATIONS
Website
www.regeneron.com
Listed
1991-04-02
Address
777 OLD SAW MILL RIVER ROAD
TARRYTOWN, NY 10591
Phone: (914) 847-7000
Technical OutlookSell
Strong SellNeutralStrong Buy
Long-Term (Tide)?– Neutral(0/3)
Medium-Term (Wave)?– Neutral(0/3)
Short-Term (Ripple)?▼ Bearish(-3/3)
MA Alignment?Mixed
Full Technical Analysis →
Fundamental OutlookNeutral
Strong SellNeutralStrong Buy
F-Score?
60
Z-Score?
100
Momentum?
48
Short Sent.?
52
Piotroski F-Score?5/9Mixed
Altman Z-Score?7.13Safe
Confidence?69%Moderate
Full Fundamental Analysis →
Short InterestModerate
Short % of Float?2.67%Low
Short Interest?2.6M
Days to Cover?3.9
Free Float95.7M
Avg Daily Volume662.9K
Settlement Date2026-08-31
Financial Health
Current Ratio?3.34Strong
Quick Ratio?2.78Strong
Cash Ratio?0.44Low
Debt/Equity?0.09Low
ValuationFAIRLY VALUEDvs 10 peers + S&P 500
Score
72/100
P/E?
Peers
100
S&P
70
18.6FAIR▾
P/B?
Peers
70
S&P
64
2.54CHEAP▾
P/S?
Peers
91
S&P
28
5.18FAIR▾
P/FCF?
Peers
63
S&P
51
21.4FAIR▾
EV/EBITDA?
Peers
63
S&P
32
18.5FAIR▾
EV/Sales?
Peers
82
S&P
34
5.20FAIR▾
Returns & Efficiency
ROE?
Peers
50
S&P
50
13.7%STRONG▾
ROA?
Peers
71
S&P
75
10.4%STRONG▾
Cash Flow & Enterprise
FCF?$3.8B
Enterprise Value?$80.7B
Fundamentals ratios updated end of day
MarketsMoversWatchlist